Data as of Dec 12
| -0.12 / -1.77%|
The 5 analysts offering 12-month price forecasts for Supernus Pharmaceuticals Inc have a median target of 12.00, with a high estimate of 13.00 and a low estimate of 8.00. The median estimate represents a +80.45% increase from the last price of 6.65.
The current consensus among 5 polled investment analysts is to Buy stock in Supernus Pharmaceuticals Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.